<DOC>
	<DOC>NCT01702974</DOC>
	<brief_summary>The aim with this study is to provide immunotherapy with vitamin D and phenylbutyrate to treatment-naive HIV infected patients to induce important antimicrobial defence mechanisms and decreased inflammation.</brief_summary>
	<brief_title>Immune Reconstitution in HIV Disease (IREHIV)</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<mesh_term>Anti-Infective Agents</mesh_term>
	<mesh_term>4-phenylbutyric acid</mesh_term>
	<criteria>Adult patients &gt;18 years not subjected to HAART. HIV1 infected patients with CD4 T cells counts &gt;200 cells/ml. Detectable plasma viral loads &gt;1000 copies/ml. Patients on HAART or other antimicrobial drugs (including bactrim). Antimicrobial drug treatment in the past month. Patients with medical contraindication for biopsy such as bleeding tendencies. Hypercalcaemia (serum calcium &gt; 3,0 mmol/L) identified at baseline. Pregnant and breast feeding women. Any known liver or kidney function abnormality, malignancy or patients treated with cardiac glycosides.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>HIV</keyword>
	<keyword>cholecalciferol</keyword>
	<keyword>sodium phenylbutyrate</keyword>
	<keyword>antimicrobial peptides</keyword>
	<keyword>immune response</keyword>
	<keyword>inflammation</keyword>
</DOC>